1490 related articles for article (PubMed ID: 26451490)
1. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Ciriello G; Gatza ML; Beck AH; Wilkerson MD; Rhie SK; Pastore A; Zhang H; McLellan M; Yau C; Kandoth C; Bowlby R; Shen H; Hayat S; Fieldhouse R; Lester SC; Tse GM; Factor RE; Collins LC; Allison KH; Chen YY; Jensen K; Johnson NB; Oesterreich S; Mills GB; Cherniack AD; Robertson G; Benz C; Sander C; Laird PW; Hoadley KA; King TA; ; Perou CM
Cell; 2015 Oct; 163(2):506-19. PubMed ID: 26451490
[TBL] [Abstract][Full Text] [Related]
2. Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.
Chen F; Ding K; Priedigkeit N; Elangovan A; Levine KM; Carleton N; Savariau L; Atkinson JM; Oesterreich S; Lee AV
Cancer Res; 2021 Jan; 81(2):268-281. PubMed ID: 33148662
[TBL] [Abstract][Full Text] [Related]
3. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
Turashvili G; Bouchal J; Baumforth K; Wei W; Dziechciarkova M; Ehrmann J; Klein J; Fridman E; Skarda J; Srovnal J; Hajduch M; Murray P; Kolar Z
BMC Cancer; 2007 Mar; 7():55. PubMed ID: 17389037
[TBL] [Abstract][Full Text] [Related]
4. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
5. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Kurozumi S; Alsaleem M; Monteiro CJ; Bhardwaj K; Joosten SEP; Fujii T; Shirabe K; Green AR; Ellis IO; Rakha EA; Mongan NP; Heery DM; Zwart W; Oesterreich S; Johnston SJ
Breast Cancer Res; 2020 Aug; 22(1):85. PubMed ID: 32782013
[TBL] [Abstract][Full Text] [Related]
6. ERBB2 mutation is associated with a worse prognosis in patients with CDH1 altered invasive lobular cancer of the breast.
Ping Z; Siegal GP; Harada S; Eltoum IE; Youssef M; Shen T; He J; Huang Y; Chen D; Li Y; Bland KI; Chang HR; Shen D
Oncotarget; 2016 Dec; 7(49):80655-80663. PubMed ID: 27811364
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
[TBL] [Abstract][Full Text] [Related]
8. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
9. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
10. A Unique FOXA1-Associated Chromatin State Dictates Therapeutic Resistance in Lobular Breast Cancer.
Blawski R; Toska E
Cancer Res; 2022 Oct; 82(20):3668-3670. PubMed ID: 36245246
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
15. Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.
Sreekumar S; Levine KM; Sikora MJ; Chen J; Tasdemir N; Carter D; Dabbs DJ; Meier C; Basudan A; Boone D; McAuliffe PF; Jankowitz RC; Lee AV; Atkinson JM; Oesterreich S
Endocrinology; 2020 Sep; 161(9):. PubMed ID: 32609836
[TBL] [Abstract][Full Text] [Related]
16. Chromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomas.
Lee S; Osmanbeyoglu HU
Breast Cancer Res; 2022 Jul; 24(1):54. PubMed ID: 35906698
[TBL] [Abstract][Full Text] [Related]
17. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: correlation with morphology and CDH1 somatic alterations.
Grabenstetter A; Mohanty AS; Rana S; Zehir A; Brannon AR; D'Alfonso TM; DeLair DF; Tan LK; Ross DS
Hum Pathol; 2020 Aug; 102():44-53. PubMed ID: 32599083
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets.
Nakagawa S; Miki Y; Miyashita M; Hata S; Takahashi Y; Rai Y; Sagara Y; Ohi Y; Hirakawa H; Tamaki K; Ishida T; Watanabe M; Suzuki T; Ohuchi N; Sasano H
Breast Cancer Res Treat; 2016 Jan; 155(1):65-75. PubMed ID: 26715212
[TBL] [Abstract][Full Text] [Related]
20. Proteomic and transcriptomic profiling identifies mediators of anchorage-independent growth and roles of inhibitor of differentiation proteins in invasive lobular carcinoma.
Tasdemir N; Ding K; Savariau L; Levine KM; Du T; Elangovan A; Bossart EA; Lee AV; Davidson NE; Oesterreich S
Sci Rep; 2020 Jul; 10(1):11487. PubMed ID: 32661241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
